FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula (I) or its stereoisomer, which are used for the treatment of a respiratory disease of cattle or domestic pigs, associated with Pasteurella multocida or Mannheimia haemolytica bacteria. In the formula (I), R1 is selected from a group including C(R11R12R13), C(=O)R11, -C(=NR14)R11; R11 is selected from a group including H and C1-6-alkyl; R12 is selected from a group including H and C1-6-alkyl; R13 is selected from a group including H, C1-6-alkyl, C6-aryl, -SR8, -OR9, -SO2R8, a nitro group; where, if R13 is OH, and R12 is methyl, then R11 cannot be H; where, if R13 is OH, and R12 is H, then R11 cannot be methyl; where, if R13 is OH, and R12 is methyl, then R11 cannot be methyl; R14 is -OR9; R2, R3 are H; R4 is -OR9; R5 is H; R6, R7 are independently selected from a group including H, C1-6-alkyl, C2-6-alkenyl, C3-10-cycloalkyl, C1-6-alkyloxy-C1-6-alkyl, C1-C6-alkyl substituted with C6-aryl, C1-C6-alkyl substituted with heteroaryl, where heteroaryl is a cyclic aromatic radical including 5-6 atoms in a ring, of which 1 atom is selected from a group consisting of S, O, and N; 0, 1, or 2 ring atoms are additional atoms independently selected from a group consisting of S, O, and N; and remaining ring atoms are C; C1-C6-alkyl substituted with heterocyclyl, where heterocyclyl is a 5-6-element monocyclic nonaromatic ring system consisting of 4-5 C atoms and 1 heteroatom selected from oxygen; or R6, R7, together with N atom, to which they are attached, can form a saturated or unsaturated heterocyclic ring containing from 3 to 12 ring atoms, where 1 ring atom is N, and where 0, 1, or 2 additional ring atoms are selected from a group including N, S, and O, remaining ring atoms are C; R8 is selected from a group consisting of C1-6-alkyl; R9, R10 are independently selected from a group including H and C1-6-alkyl; L is selected from a group consisting of C1-6-alkyl; M is selected from a group consisting of C6-aryl, heteroaryl, where heteroaryl is a cyclic aromatic radical consisting of 5-6 ring atoms, where 1 ring atom is selected from a group consisting of S and N, and remaining ring atoms are C; C2-4-alkenyl; G is selected from a group consisting of -C≡C-; Y is selected from a group consisting of C6-aryl; X is selected from a group consisting of -C(=O)-. The invention also relates to a pharmaceutical composition, methods for the treatment of a respiratory disease of cattle or domestic pigs, associated with Pasteurella multocida or Mannheimia haemolytica, or an infection caused by the specified bacteria, using the proposed compounds, and their use for the preparation of a drug for the treatment of the above-mentioned diseases or infections.
EFFECT: obtaining compounds for the treatment of diseases of cattle and domestic pigs.
10 cl, 2 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS USABLE FOR THE TREATMENT OF RESPIRATORY DISEASE IN CATTLE OR PIGS | 2017 |
|
RU2775529C2 |
| ORALLY ADMINISTERED COMBINATIONS OF BETA-LACTAM ANTIBIOTICS AND AVIBACTAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | 2020 |
|
RU2825281C1 |
| HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | 2008 |
|
RU2451019C2 |
| FLUORINATED LIGANDS FOR TARGETING PERIPHERAL BENZODIAZEPINE RECEPTORS | 2007 |
|
RU2468014C2 |
| AMINO-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND USE THEREOF AS PHARMACEUTICAL AGENTS | 2012 |
|
RU2605600C2 |
| DUAL-ACTING ANTIHYPERTENSIVE COMPOUNDS, METHODS FOR PREPARING THEM, BASED PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE COMPOUNDS | 2008 |
|
RU2476427C2 |
| COMPOUNDS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER AND OVARIAN CANCER | 2019 |
|
RU2776897C2 |
| SUBSTITUTED CHROMAN-6-YLOXY-CYCLOALKANES AND USE THEREOF AS MEDICAMENTS | 2014 |
|
RU2666350C2 |
| NEPRILYSIN INHIBITORS | 2011 |
|
RU2605557C2 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
